RATIONALE: Pulmonary arterial hypertension (PAH) is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arterioles. We and others have demonstrated chromosomal abnormalities and increased DNA damage in PAH lung vascular cells, but their timing and role in disease pathogenesis is unknown. OBJECTIVES: We hypothesized that if DNA damage predates PAH, it might be an intrinsic cell property that is present outside the diseased lung. METHODS: We measured DNA damage, mutagen sensitivity, and reactive oxygen species (ROS) in lung and blood cells from patients with Group 1 PAH, their relatives, and unrelated control subjects. MEASUREMENTS AND MAIN RESULTS: Baseline DNA damage was significantly elevated in PAH, both in pulmonary artery endothelial cells (P < 0.05) and peripheral blood mononuclear cells (PBMC) (P < 0.001). Remarkably, PBMC from unaffected relatives showed similar increases, indicating this is not related to PAH treatments. ROS levels were also higher (P < 0.01). DNA damage correlated with ROS production and was suppressed by antioxidants (P < 0.001). PBMC from patients and relatives also showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001). Results were consistent across idiopathic, heritable, and associated PAH groups. CONCLUSIONS: Levels of baseline and mutagen-induced DNA damage are intrinsically higher in PAH cells. Similar results in PBMC from unaffected relatives suggest this may be a genetically determined trait that predates disease onset and may act as a risk factor contributing to lung vascular remodeling following endothelial cell injury. Further studies are required to fully characterize mutagen sensitivity, which could have important implications for clinical management.
RATIONALE: Pulmonary arterial hypertension (PAH) is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arterioles. We and others have demonstrated chromosomal abnormalities and increased DNA damage in PAH lung vascular cells, but their timing and role in disease pathogenesis is unknown. OBJECTIVES: We hypothesized that if DNA damage predates PAH, it might be an intrinsic cell property that is present outside the diseased lung. METHODS: We measured DNA damage, mutagen sensitivity, and reactive oxygen species (ROS) in lung and blood cells from patients with Group 1 PAH, their relatives, and unrelated control subjects. MEASUREMENTS AND MAIN RESULTS: Baseline DNA damage was significantly elevated in PAH, both in pulmonary artery endothelial cells (P < 0.05) and peripheral blood mononuclear cells (PBMC) (P < 0.001). Remarkably, PBMC from unaffected relatives showed similar increases, indicating this is not related to PAH treatments. ROS levels were also higher (P < 0.01). DNA damage correlated with ROS production and was suppressed by antioxidants (P < 0.001). PBMC from patients and relatives also showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001). Results were consistent across idiopathic, heritable, and associated PAH groups. CONCLUSIONS: Levels of baseline and mutagen-induced DNA damage are intrinsically higher in PAH cells. Similar results in PBMC from unaffected relatives suggest this may be a genetically determined trait that predates disease onset and may act as a risk factor contributing to lung vascular remodeling following endothelial cell injury. Further studies are required to fully characterize mutagen sensitivity, which could have important implications for clinical management.
Entities:
Keywords:
BMPR2; DNA damage; genetic susceptibility; reactive oxygen species
Authors: Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Tal Schechter; Stephan Leucht; Eric Bouffet; Ernest Cutz; Adam Gassas; Annie Huang; Ute Bartels; Tilman Humpl; John Doyle Journal: Biol Blood Marrow Transplant Date: 2012-09-26 Impact factor: 5.742
Authors: Emma K Larkin; John H Newman; Eric D Austin; Anna R Hemnes; Lisa Wheeler; Ivan M Robbins; James D West; John A Phillips; Rizwan Hamid; James E Loyd Journal: Am J Respir Crit Care Med Date: 2012-08-23 Impact factor: 21.405
Authors: Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel Journal: Am J Respir Crit Care Med Date: 2003-12-30 Impact factor: 21.405
Authors: Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Lan Zhao; Ali Ashek; Lei Wang; Wei Fang; Swati Dabral; Olivier Dubois; John Cupitt; Soni Savai Pullamsetti; Emanuele Cotroneo; Hazel Jones; Gianpaolo Tomasi; Quang-De Nguyen; Eric O Aboagye; Mona A El-Bahrawy; Gareth Barnes; Luke S Howard; J Simon R Gibbs; Willy Gsell; Jian-Guo He; Martin R Wilkins Journal: Circulation Date: 2013-07-30 Impact factor: 29.690
Authors: Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova Journal: Am J Respir Crit Care Med Date: 2017-02-15 Impact factor: 21.405
Authors: Pin-I Chen; Aiqin Cao; Kazuya Miyagawa; Nancy F Tojais; Jan K Hennigs; Caiyun G Li; Nathaly M Sweeney; Audrey S Inglis; Lingli Wang; Dan Li; Matthew Ye; Brian J Feldman; Marlene Rabinovitch Journal: JCI Insight Date: 2017-01-26